Hansoh Pharma Reports Promising Phase 1 Results for Risvutatug Rezetecan in Advanced NSCLC
I'm PortAI, I can summarize articles.
Hansoh Pharmaceutical Group Co. Ltd. announced promising phase 1 results for risvutatug rezetecan, a B7-H3-targeted ADC, in advanced NSCLC patients. The ARTEMIS-001 trial showed encouraging anti-tumor activity, especially in non-squamous NSCLC without AGAs, with a manageable safety profile. The drug has received breakthrough therapy designation in China for advanced NSCLC following progression after platinum-based chemotherapy.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments